FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3018192110> ?p ?o ?g. }

• W3018192110 endingPage "97" @default.
• W3018192110 startingPage "85" @default.
• W3018192110 abstract "BackgroundThe clinical impact of the positivity of the Deauville scale (DS) of positron emission tomography (PET) performed at the end of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in patients with advanced Hodgkin lymphoma (HL), in terms of providing rationale to shift poor responders onto a more intensive regimen, remain to be validated by histopathology.Patients and methodsThis prospective trial involved patients with stage IIB/IV HL who after six ABVD cycles underwent PET (PET6) and core-needle cutting biopsy (CNCB) of 2-deoxy-2[F-18] fluoro-d-glucose (FDG)-avid lymph nodes. Patients received high-dose chemotherapy/autologous haematopoietic stem cell rescue (HDCT/AHSCR) if CNCB was positive for HL, alternatively, if CNCB or PET was negative, received observation or consolidation radiotherapy (cRT) on residual nodal masses, as initially planned. The end-point was 5-year progression-free survival (PFS).ResultsIn all, 43 of the 169 (25%) evaluable patients were PET6 positive (DS 4, 32; DS 5, 11). Among them, histology showed malignancy (HL) in 100% of DS 5 scores and in 12.5% of DS 4 scores. Fifteen patients with positive biopsy received HDCT/AHSCR, whereas 28 patients with negative biopsy, as well as 126 patients with negative PET6, continued the original plan (cRT, 78 patients; observation, 76 patients). The 5-year PFS in the negative PET6 group, negative biopsy group and positive biopsy group was 95.4%, 100% and 52.5%, respectively.ConclusionDS positivity of end-of-ABVD PET in advanced HL carried a certain number of CNCB-proven non-malignant FDG-uptakes. The DS 4 scores which were found to have negative histology appeared to benefit from continuing the original non-intensive therapeutic plane as indicated by the successful outcome in more than 95% of them by obtaining similar 5-year PFS to the PET6-negative group. By contrast, the DS 5 score had consistently positive histology and was associated with unsuccessful conventional therapy, promptly requiring treatment intensification or innovative therapeutic approaches." @default.
• W3018192110 created "2020-05-01" @default.
• W3018192110 creator A5003687592 @default.
• W3018192110 creator A5017757167 @default.
• W3018192110 creator A5025117598 @default.
• W3018192110 creator A5025670941 @default.
• W3018192110 creator A5032330087 @default.
• W3018192110 creator A5047732268 @default.
• W3018192110 creator A5049072084 @default.
• W3018192110 creator A5056123427 @default.
• W3018192110 creator A5057031849 @default.
• W3018192110 creator A5057084037 @default.
• W3018192110 creator A5059488532 @default.
• W3018192110 creator A5060522685 @default.
• W3018192110 creator A5074115401 @default.
• W3018192110 creator A5078017458 @default.
• W3018192110 creator A5084259837 @default.
• W3018192110 creator A5086760651 @default.
• W3018192110 date "2020-06-01" @default.
• W3018192110 modified "2023-10-16" @default.
• W3018192110 title "2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma" @default.
• W3018192110 cites W1671678474 @default.
• W3018192110 cites W2037602782 @default.
• W3018192110 cites W2051650384 @default.
• W3018192110 cites W2072931049 @default.
• W3018192110 cites W2083246409 @default.
• W3018192110 cites W2086160378 @default.
• W3018192110 cites W2098663478 @default.
• W3018192110 cites W2118661923 @default.
• W3018192110 cites W2119147717 @default.
• W3018192110 cites W2125616358 @default.
• W3018192110 cites W2131900456 @default.
• W3018192110 cites W2137961400 @default.
• W3018192110 cites W2140419795 @default.
• W3018192110 cites W2142780851 @default.
• W3018192110 cites W2143214257 @default.
• W3018192110 cites W2170821702 @default.
• W3018192110 cites W2310716991 @default.
• W3018192110 cites W2469052042 @default.
• W3018192110 cites W2516029706 @default.
• W3018192110 cites W2583043639 @default.
• W3018192110 cites W2767762193 @default.
• W3018192110 cites W2784654265 @default.
• W3018192110 cites W2899940507 @default.
• W3018192110 cites W2944981740 @default.
• W3018192110 cites W3006603819 @default.
• W3018192110 cites W4236235343 @default.
• W3018192110 doi "https://doi.org/10.1016/j.ejca.2020.03.008" @default.
• W3018192110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32334339" @default.
• W3018192110 hasPublicationYear "2020" @default.
• W3018192110 type Work @default.
• W3018192110 sameAs 3018192110 @default.
• W3018192110 citedByCount "8" @default.
• W3018192110 countsByYear W30181921102020 @default.
• W3018192110 countsByYear W30181921102021 @default.
• W3018192110 countsByYear W30181921102022 @default.
• W3018192110 countsByYear W30181921102023 @default.
• W3018192110 crossrefType "journal-article" @default.
• W3018192110 hasAuthorship W3018192110A5003687592 @default.
• W3018192110 hasAuthorship W3018192110A5017757167 @default.
• W3018192110 hasAuthorship W3018192110A5025117598 @default.
• W3018192110 hasAuthorship W3018192110A5025670941 @default.
• W3018192110 hasAuthorship W3018192110A5032330087 @default.
• W3018192110 hasAuthorship W3018192110A5047732268 @default.
• W3018192110 hasAuthorship W3018192110A5049072084 @default.
• W3018192110 hasAuthorship W3018192110A5056123427 @default.
• W3018192110 hasAuthorship W3018192110A5057031849 @default.
• W3018192110 hasAuthorship W3018192110A5057084037 @default.
• W3018192110 hasAuthorship W3018192110A5059488532 @default.
• W3018192110 hasAuthorship W3018192110A5060522685 @default.
• W3018192110 hasAuthorship W3018192110A5074115401 @default.
• W3018192110 hasAuthorship W3018192110A5078017458 @default.
• W3018192110 hasAuthorship W3018192110A5084259837 @default.
• W3018192110 hasAuthorship W3018192110A5086760651 @default.
• W3018192110 hasBestOaLocation W30181921101 @default.
• W3018192110 hasConcept C126322002 @default.
• W3018192110 hasConcept C126838900 @default.
• W3018192110 hasConcept C2775842073 @default.
• W3018192110 hasConcept C2775934546 @default.
• W3018192110 hasConcept C2776305933 @default.
• W3018192110 hasConcept C2776694085 @default.
• W3018192110 hasConcept C2776755627 @default.
• W3018192110 hasConcept C2777132456 @default.
• W3018192110 hasConcept C2779429289 @default.
• W3018192110 hasConcept C2780964509 @default.
• W3018192110 hasConcept C2989005 @default.
• W3018192110 hasConcept C71924100 @default.
• W3018192110 hasConceptScore W3018192110C126322002 @default.
• W3018192110 hasConceptScore W3018192110C126838900 @default.
• W3018192110 hasConceptScore W3018192110C2775842073 @default.
• W3018192110 hasConceptScore W3018192110C2775934546 @default.
• W3018192110 hasConceptScore W3018192110C2776305933 @default.
• W3018192110 hasConceptScore W3018192110C2776694085 @default.
• W3018192110 hasConceptScore W3018192110C2776755627 @default.
• W3018192110 hasConceptScore W3018192110C2777132456 @default.
• W3018192110 hasConceptScore W3018192110C2779429289 @default.
• W3018192110 hasConceptScore W3018192110C2780964509 @default.
• W3018192110 hasConceptScore W3018192110C2989005 @default.

• next